Alkahest, Inc.
75 Shoreway Road, Suite D
San Carlos
California
94070
United States
Tel: 650-801-0474
Fax: 650-801-0480
Website: http://www.alkahest.com/
Email: info@alkahest.com
About Alkahest, Inc.
At Alkahest, we strive to lead the way towards effective therapies for patients suffering from diseases associated with the detrimental processes of aging. We believe that as an industry, we simply haven’t done enough to help drive solutions for the most under-treated and devastating diseases affecting this growing demographic. We want to help.
Aging is the dominant risk factor in degenerative diseases. Many of the pressing age-related and neurodegenerative diseases have a profound impact on patients and their caregivers, yet have very limited treatment options. Alkahest has embarked upon a simple but elegant approach to treat disorders of aging by capitalizing on the body’s own natural regulatory and communication mechanisms, leveraging the plasma proteome. The promise of this science, and the potential to make a difference to patients around the world, was the founding principle of Alkahest.
For all of the great progress we have made so far, we credit our dedicated and impassioned team for driving our successes. Our culture is warm and supportive, genuine and ethical, rigorous and scientific, and collaborative yet entrepreneurial. Based in Silicon Valley, home to many leaders in the biotechnology industry, the heart of our culture is scientific innovation. We work hard, yet we have fun while we’re doing so. We are passionate about both our collegial atmosphere as well as working together on cutting-edge therapies that will change the lives of patients. We know we have a lot further to go, and we’re ready for the long haul.
43 articles with Alkahest, Inc.
-
Several biotech companies backed by billions are working on different approaches to developing the next big anti-aging therapy - from blood experiments to cell reprogramming.
-
BioSpace Movers & Shakers, July 30, 2021
7/30/2021
Biopharma and life science companies strengthen their leadership teams and boards with these Movers & Shakers. -
Clinical Catch-Up: March 8-12
3/15/2021
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more. -
Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s Disease
3/8/2021
Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases and a subsidiary of Grifols, today announced it will be delivering a presentation of data from a completed study of its therapeutic plasma fraction candidate, GRF6021, in subjects with Parkinson’s disease (PD) and cognitive impairment at the virtual 15th International Conference on Alzheimer’s and Parkinson’s Diseases.
-
Alkahest Announces Peer-Reviewed Publication Demonstrating Safety and Tolerability of GRF6019 in Patients with Mild-to-Moderate Alzheimer’s Disease
1/28/2021
GRF6019 was safe and well-tolerated, and patients experienced no cognitive decline and minimal functional decline
-
The transaction, which is set to conclude in early 2021, will give Grifols access to Alkahest’s four product candidates.
-
Alkahest Provides Corporate Update
7/9/2020
Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today provided a corporate update. “Since early this year, we have continued to make great strides in advancing our clinical assets, including initiation of a pilot phase 2 for our newest clinical therapeutic, AKST1210,” said Karoly Nikolich, Ph.D., chief executive officer of Alkahest. “Whils
-
Clinical Catch-Up: May 31-June 5
6/8/2020
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look. -
Alkahest Announces Initiation of Phase 2 Study AKST1210-201 Exploring Treatment of Cognitive Impairment in End Stage Renal Disease PatientsStudy to explore extracorporeal removal of Beta-2 microglobulin
6/1/2020
Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, announced the initiation of a clinical study to explore the use of an extracorporeal medical device to remove excess Beta-2 microglobulin from circulation for the treatment of cognitive impairment in patients undergoing hemodialysis for end stage renal disease.
-
Clinical Catch-Up: February 10-14
2/17/2020
It was a very busy week for clinical trial news. Here’s a look. -
Alkahest Announces Initiation of Phase 2b Clinical Trial of AKST4290 in Patients with Treatment-Naïve Wet Age-Related Macular Degeneration
2/10/2020
SAN CARLOS, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced the initiation of a phase 2b clinical trial of its orally administered small molecule CCR3 inhibitor, AKST4290. The company has dosed the first subject in AKST4290-205 (PHTHALO), which will assess the effects of AKST4290 on visual acuity with loading doses of anti-VEGF in treatm
-
Clinical Catch-Up: February 3-7, 2020
2/10/2020
Although it was a relatively slow week for clinical trial updates, there were still a number of announcements. Here’s a look. -
Alkahest Initiates a Phase 2 Clinical Trial of AKST4290 in Parkinson’s Disease with Funding from The Michael J. Fox Foundation
2/4/2020
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the dosing of the first patient in a phase 2 clinical trial of AKST4290, an orally administered CCR3 inhibitor, for treatment of Parkinson’s disease.
-
Clinical Catch-Up: December 16-20
12/23/2019
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look. -
Alkahest Initiates Phase 2 Clinical and Mechanistic Trial of AKST4290 on Choroidal Blood Flow in Age-Related Macular Degeneration
12/17/2019
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the initiation of a phase 2 clinical trial of its orally administered small molecule CCR3 inhibitor, AKST4290.
-
Clinical Catch-Up: December 2-5
12/9/2019
It was, as usual, a pretty busy week in clinical trial news. Here’s a look. -
Alkahest Presents Data from Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease
12/9/2019
Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, presented data this weekend from its phase 2a study, AKST6019-201, in mild-to-moderate Alzheimer’s Disease (AD).
-
Alkahest to Present New Data from Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease at the Clinical Trials in Alzheimer’s Disease (CTAD) Conference
12/2/2019
Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced an oral presentation of data from its phase 2a study ALK6019-201 in mild-to-moderate Alzheimer’s Disease at the 12th Clinical Trials on Alzheimer’s Disease from December 4 – 7, 2019 in San Diego.
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
Clinical Catch-up for August 19-23
8/26/2019
Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week.